No Benefit to Extensive Cancer Screening in Unprovoked Venous Thromboembolism

Share this content:
Aggressive screening of patients with VTE may actually cause more harm than benefit.
Aggressive screening of patients with VTE may actually cause more harm than benefit.

Unprovoked venous thromboembolism (VTE) in some cases may be a sign of occult cancer.  However, extensive cancer screening tests do not appear to translate into benefits in terms of lower morbidity and mortality in patients with unprovoked VTE, according to a new Canadian study. Researchers from the University of Ottawa report in the Annals of Internal Medicine that aggressive screening is often considered in these patients but there does not appear to be a clear benefit and there may be potential harms with extensive screening.

“The studies until now have been too small to make a determination of what is the underlying risk in an unexplained blood clot,” said Marc Carrier, MD, who is an associate professor at the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario. “What if we do more aggressive screening? Are we making a difference or spending a lot of money for nothing?”

 

THE STUDY 

Dr Carrier and his colleagues conducted a systematic review and meta-analysis of individual patient data to estimate the prevalence of occult cancer in patients with unprovoked VTE.  They looked at subgroups based on age and different types of screening. Their sources included MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials from November 2007 to mid-January 2016. The researchers also searched conference proceedings of the International Society on Thrombosis and Haemostasis and the American Society of Hematology from 2007 to 2015.

A total of 1216 articles were identified. Among these, 23 full texts were assessed for eligibility and 10 studies qualified. Individual data were obtained for 2316 patients (mean age, 60 years). In this cohort, 58% of patients received extensive screening. A significant number of the patients (N = 2052) were enrolled in the studies before any occult cancer screening procedures.  

Page 1 of 3
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs